Article
The clinical and molecular landscape of diffuse hemispheric glioma, H3 G34-mutant.
Neuro-oncology - 30 Jul 2025
Le Rhun Emilie, Bink Andrea, Felsberg Joerg, Gramatzki Dorothee, Brandner Sebastian, Benhamida Jamal K, Wick Antje, Tonn Joerg C, Mohme Malte, Tabatabai Ghazaleh, Capper David, Snuderl Matija, Razis Evangelia, Ronellenfitsch Michael W, Neidert Nicolas, Ng Ho-Keung, Pohl Ute, Bale Tejus, Quach Stefanie, Rieger David, Schüller Ulrich, Onken Julia, Drüschler Katharina, Maurage Claude-Alain, Regli Luca, Healy Estelle, Graham Maya, Hortobagyi Tibor, Paine Simon, Bridges Leslie, Lausova Tereza, Medici Valentina, Sievers Philipp, Schrimpf David, Wick Wolfgang, Sahm Felix, Reifenberger Guido, von Deimling Andreas, Weller Michael
Abstract excerpt
BACKGROUND: Diffuse hemispheric glioma, histone 3 (H3) G34-mutant, has been newly defined in the 2021 World Health Organization (WHO) classification of central nervous system tumors. Here we sought to define the prognostic roles of clinical, neuroimaging, pathological, and molecular features of these tumors. METHODS: We retrospectively assembled a cohort of 114 patients (median age 22 years) with diffuse...
Topics
Join the communities discussing this publication.